Growth hormone receptor expression and function in pituitary adenomas

Clausen, L.R.; Kristiansen, Mikkel T; Rasmussen, Lars Melholt; Billestrup, Nils; Blaabjerg, Ole; Ledet, Thomas; Jørgensen, Jens O. L.

doi:10.1111/j.1365-2265.2004.02022.x

Cited by 3 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A known mitogenic hormone, such as GH, could increase the rate of tumour recurrence or enlargement in patients with a known or unknown residual tumour. Non-functioning pituitary adenoma (NFPA) cells have been shown to express GH receptors in vitro (14). Excess GH, as seen in acromegaly, has been associated with an increased prevalence of premalignant colonic polyps and benign prostatic hyperplasia, but an increased prevalence of cancer has not been demonstrated (15)(16)(17)(18).…”

Section: Introductionmentioning

confidence: 99%

Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy

Olsson

Buchfelder

Schlaffer

et al. 2009

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: An important safety issue with GH replacement therapy (GHRT) in hypopituitary patients with a history of a pituitary adenoma is the risk for tumour recurrence or enlargement. Design: Case-control study. Subjects and methods: We studied tumour progression rate in 121 patients with hypopituitarism on the basis of non-functioning pituitary adenomas (NFPA) receiving long-term GHRT. A group of 114 NFPA patients not receiving GHRT who were matched in terms of duration of follow-up, gender, age, age at diagnosis and radiotherapy status were used as a control population. The average duration of GHRT was 10G4 years (range 2-17).

show abstract

Section: Introductionmentioning

confidence: 99%

Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy

Olsson

Buchfelder

Schlaffer

et al. 2009

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

IGF1 induces cell proliferation in human pituitary tumors – Functional blockade of IGF1 receptor as a novel therapeutic approach in non-functioning tumors

Rubinfeld

Kammer

Cohen

et al. 2014

Molecular and Cellular Endocrinology

View full text Add to dashboard Cite

Hormone Receptor Expression in Craniopharyngiomas

et al. 2010

View full text Add to dashboard Cite

The present preliminary data point to a correlation between estrogen and growth hormone receptor expression and proliferation indexes with tumor size in craniopharyngiomas. Because of the small cohort of tumors, these data require expansion and validation. This is the first report about leptin expression in this tumor entity. These findings should prompt careful consideration of hormonal replacement therapy regimens in patients with tumor remnants and evidence of respective receptor expression.

show abstract

Growth hormone receptor expression and function in pituitary adenomas

Abstract: GH receptors are expressed in human pituitary adenoma cells but their functional role is uncertain. GH and IGF-I do not consistently influence the proliferation of cultured pituitary adenoma cells.

Cited by 3 publications

References 33 publications

Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy

Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy

IGF1 induces cell proliferation in human pituitary tumors – Functional blockade of IGF1 receptor as a novel therapeutic approach in non-functioning tumors

Hormone Receptor Expression in Craniopharyngiomas

Contact Info

Product

Resources

About